# Beacon Therapeutics: Research, Alachua, United Kingdom

> Beacon Therapeutics: Beacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023, dedicated to saving and restoring vision for...

Source: https://millionrounds.com/startup/beacon-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United Kingdom · [Research startup](https://millionrounds.com/companies)

# Beacon Therapeutics

Beacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023, dedicated to saving and restoring vision for patients with retinal diseases that can lead to blindness.

Funding reported Last round: Series B

Research Alachua, United Kingdom

Company summary

- **Founded:** 2023 3 years old
- **Team:** 96 51 to 200 people
- **Funding reported:** 290.1M as listed, currency not stated
- **Last round:** Series B Jun 2024

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Beacon Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Beacon Therapeutics

Beacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023, dedicated to saving and restoring vision for patients with retinal diseases that can lead to blindness.

The company specializes in developing adeno-associated virus (AAV) gene therapies to deliver therapeutic proteins directly to the retina. Headquartered in Alachua, Florida, with additional offices in London and Cambridge, Beacon has raised approximately $367 million to support its clinical trials. The company's pipeline includes AGTC-501, a late-stage candidate for treating X-linked Retinitis Pigmentosa (XLRP), currently in Phase II clinical trials. Additionally, Beacon is developing therapies for Cone-Rod Dystrophy (CRD) and Dry Age-Related Macular Degeneration (dAMD), both in preclinical stages. Beacon Therapeutics serves patients in the UK and the US, focusing on those affected by rare and prevalent ocular diseases. The company operates on a B2G business model, partnering with healthcare systems and public health entities to advance its mission.

## What company datasets say Beacon Therapeutics raised

Funding, as reported

Reported in all **290.1M** in the source's currency

Rounds **2**

Last round **Series B**

Last round size **75M**

Last round date **Jun 2024**

Investors listed **6**

## Funding filed with regulators

Beacon Therapeutics filed 9 raises, $221M in all. Filings say how much was sold and to how many investors; they never name the investors.

- Dec 2025 **$49M** UK share allotment
- Jun 2025 **$40M** UK share allotment
- Dec 2024 **$35M** UK share allotment
- Jun 2024 **$31M** UK share allotment
- Dec 2023 **$21M** UK share allotment
- Aug 2023 **$12M** UK share allotment
- Mar 2023 **$14M** UK share allotment
- Mar 2023 **$19M** UK share allotment
- Dec 2022 **Amount not stated** UK share allotment

## Founders and team

From Beacon Therapeutics's own website: 6 on the team.

- **Lance Baldo** Chief Executive Officer
- **Abraham Scaria** Chief Scientific Officer
- **Brian Mullan** Chief Technical Officer
- **Daniel Chung** Chief Medical Officer
- **Ryan Robinson** Chief Financial Officer
- **Khurem Farooq** Independent Director

## The company, in detail

What they build

Known for

health care strategic partnerships scalable production biotechnology research distribution manufacturing disease modification genetic eye diseases gmp manufacturing aav vectors cone-rod dystrophy medical research x-linked retinitis pigmentosa retinal diseases vision restoration regulatory affairs

Built with from their website

Yoast SEO Contact Form 7 Google Tag Manager WordPress.org PWA Font Awesome Cloudflare DNS CloudFlare Viewport Meta Platform.sh

+8 more

Yoast HTTP/3 Cloudflare Rocket Loader Cloudflare Browser Insights Microsoft Office Wordpress Microsoft Exchange Online CloudFlare CDN

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 8731, 2836
- **Region:** England
- **Part of:** Syncona Limited
- **Revenue:** 325k a year, as listed
- **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/beacon-therapeutics)

## Research in United Kingdom

Startups like it

- [**Isomorphic Labs** London · founded 2021 *Raised*](https://millionrounds.com/company/isomorphic-labs)
- [**Basecamp Research** London · founded 2019 *Raised*](https://millionrounds.com/company/basecamp-research)
- [**Callosum** London · founded 2025 *Raised*](https://millionrounds.com/company/callosum)
- [**Artios** Babraham · founded 2016 *Raised*](https://millionrounds.com/company/artios)
- [**First Light Fusion** Yarnton · founded 2011 *Raised*](https://millionrounds.com/company/first-light-fusion)
- [**IMU Biosciences** London · founded 2019 *Raised*](https://millionrounds.com/company/imu-biosciences)
- [**Orbital Industries** London · founded 2022 *Raised*](https://millionrounds.com/company/orbital-industries)
- [**Genomics** Oxford · founded 2014 *Raised*](https://millionrounds.com/company/genomics)

## Is this your company?

Add your raise, your deck and your story, and put Beacon Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)